What's Happening?
Protego Biopharma, a San Diego-based biotechnology company, has appointed Dr. Jae B. Kim as its new Chief Medical Officer. Dr. Kim brings extensive experience in advancing novel therapies across multiple therapeutic areas, including cardiovascular and
rare diseases. He previously served as Chief Medical Officer at Septerna and Design Therapeutics, contributing to the development and approval of several drugs. At Protego, Dr. Kim will lead the global registration program for PROT-001, a small molecule pharmacological chaperone designed to treat light chain amyloidosis. The company focuses on developing small-molecule drugs targeting protein misfolding pathways to treat rare and systemic diseases.
Why It's Important?
Dr. Kim's appointment is significant for Protego Biopharma as it seeks to advance its lead program, PROT-001, into pivotal studies. His expertise in drug development and approval processes is expected to enhance the company's efforts to address rare diseases with serious unmet medical needs. The focus on protein misfolding pathways represents a promising approach to treating conditions that currently lack effective therapies. This development could potentially change the standard of care for light chain amyloidosis and improve patient outcomes, highlighting the importance of innovative approaches in the biotechnology sector.
